Abiopharma

SPRUCE BIOSCIENCES, INC. (SPRB)

Symbol	SPRB
Name	SPRUCE BIOSCIENCES, INC.
Sector	HEALTH CARE
Region	North America
Industry	-
Address	94080 United States CA 611 Gateway Boulevard Suite 740
Telephone	(415) 655-4168
Fax	—
Email	—
Website	http://www.sprucebio.com/
Incorporation	US
Incorporated On	2016
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	BDO USA, LLP;
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0001683553
Description	Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. The company has a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Additional info from NASDAQ: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Additional info from OTC: Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. The company has a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options.

2026-06-29 12:00

Spruce Biosciences Joins the Russell 3000® Index

2026-06-22 12:00

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

2026-06-15 12:00

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

2026-06-08 20:05

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

2026-05-28 20:05

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

2026-05-27 20:05

Spruce Biosciences to Participate in Upcoming Conferences in June

2026-05-26 20:30

SPIEGELMAN DANIEL K 🟢 acquired 1.7K shares (1 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) at $52.70 Transaction Date: May 21, 2026 | Filing ID: 000002

2026-05-26 20:30

SIMPSON CAMILLA V 🟢 acquired 1.7K shares (1 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) at $52.70 Transaction Date: May 21, 2026 | Filing ID: 000002

2026-05-26 20:30

GREY MICHAEL G 🟢 acquired 1.7K shares (1 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) at $52.70 Transaction Date: May 21, 2026 | Filing ID: 000002

2026-05-26 20:30

Barretto-Ko Percival 🟢 acquired 1.7K shares (1 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) at $52.70 Transaction Date: May 21, 2026 | Filing ID: 000002

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07579910	Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidos…	Phase3	MPS IIIB	Not_Yet_Recruiting	2026-12-01	2033-08-01	ClinicalTrials.gov
NCT05370521	A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary…	Phase2	Polycystic Ovary Syndrome	Terminated	2022-05-15	2023-08-31	ClinicalTrials.gov
NCT05128942	A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Chil…	Phase2	Congenital Adrenal Hyperplasia	Terminated	2021-12-10	2025-01-31	ClinicalTrials.gov
NCT04544410	A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Dose…	Phase2	Congenital Adrenal Hyperplasia	Terminated	2021-02-22	2025-01-31	ClinicalTrials.gov
NCT04457336	A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH	Phase2	Congenital Adrenal Hyperplasia	Terminated	2020-08-26	2024-05-23	ClinicalTrials.gov
NCT03687242	Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Co…	Phase2	Congenital Adrenal Hyperplasia	Completed	2018-09-06	2019-08-09	ClinicalTrials.gov
NCT03257462	Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia	Phase2	Congenital Adrenal Hyperplasia	Completed	2017-07-12	2019-03-29	ClinicalTrials.gov

Total clinical trials: 7

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
Tralesinidase alfa (TA)	Other	Phase PHASE3	MPS IIIB	NOT_YET_RECRUITING	NCT07579910
SPR001	Other	Phase PHASE2	Congenital Adrenal Hyperplasia	COMPLETED	NCT03687242
Tildacerfont/Placebo	Other	Phase PHASE2	Congenital Adrenal Hyperplasia	TERMINATED	NCT04457336
Tildacerfont/Placebo	Other	Phase PHASE2	Congenital Adrenal Hyperplasia	TERMINATED	NCT04544410
Placebo	Other	Phase PHASE2	Polycystic Ovary Syndrome	TERMINATED	NCT05370521
Tildacerfont	Other	Phase PHASE2	Polycystic Ovary Syndrome	TERMINATED	NCT05370521
SPR001	Other	Phase PHASE2	Congenital Adrenal Hyperplasia	COMPLETED	NCT03257462
Tildacerfont	Other	Phase PHASE2	Congenital Adrenal Hyperplasia	TERMINATED	NCT05128942

Total products: 13